drugset / Trial / NCT02085265
Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
Phase 2
Terminated
23 enrolled
Sunnybrook Health Sciences Centre
Alzheimer's Drug Discovery Foundation · collabWeston Brain Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting enzyme inhibitor (ACEI).
Timeline
- Start
- 2014-03
- Primary completion
- 2025-02-28
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Perindopril | Small molecule | 2 mg | — |
| Comparator | Perindopril | Small molecule | 4 mg | — |
| Comparator | Perindopril | Small molecule | 8 mg | — |
| Subject | Telmisartan | Other / unclassified | 40 mg | — |
| Subject | Telmisartan | Other / unclassified | 80 mg | — |